Intellia Therapeutics' stock plummeted 8.12% during intraday trading on Monday, reflecting investor concerns about the company's recent financial performance and broader market pressures.

The decline follows the company's first-quarter results, which showed revenue of $15.048 million, representing a year-over-year decrease of approximately 9.6%. While the net loss per share of $0.81 beat analyst expectations and narrowed from the previous year, the revenue drop raised significant concerns about cash burn rates and the pace of pipeline advancement for this gene-editing company that has not yet commercialized any products.

Adding to the downward pressure was continued weakness in the broader biotechnology sector, with key collaboration partner Regeneron Pharmaceuticals declining 10.32% on the same day. This sector-wide negative sentiment amplified concerns about Intellia's prospects and contributed to the stock's significant intraday decline.